Rhumbline Advisers Buys New Stake in Mural Oncology plc (NASDAQ:MURA)

Rhumbline Advisers purchased a new position in Mural Oncology plc (NASDAQ:MURA) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 10,786 shares of the company’s stock, valued at approximately $34,000.

Separately, Harbor Capital Advisors Inc. bought a new stake in shares of Mural Oncology in the second quarter worth about $115,000. Institutional investors and hedge funds own 80.21% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Rodman & Renshaw initiated coverage on Mural Oncology in a research note on Friday, June 28th. They set a “buy” rating and a $15.00 price target for the company.

Insider Transactions at Mural Oncology

In other news, CEO Caroline Loew sold 12,531 shares of Mural Oncology stock in a transaction on Monday, July 8th. The stock was sold at an average price of $2.91, for a total transaction of $36,465.21. Following the completion of the sale, the chief executive officer now directly owns 240,391 shares in the company, valued at $699,537.81. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.06% of the company’s stock.

Mural Oncology Stock Performance

Shares of NASDAQ MURA opened at $3.13 on Wednesday. Mural Oncology plc has a 12-month low of $2.88 and a 12-month high of $17.00. The firm’s 50-day moving average price is $3.27 and its 200-day moving average price is $3.55.

Mural Oncology (NASDAQ:MURA) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($1.86) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.90) by $0.04. Analysts anticipate that Mural Oncology plc will post -7.54 earnings per share for the current fiscal year.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.